# A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

> **NCT06720987** · PHASE1 · RECRUITING · sponsor: **Kumquat Biosciences Inc.** · enrollment: 140 (estimated)

## Conditions studied

- KRAS G12C Mutation
- KRAS G12S Mutation
- Solid Tumor Malignancies
- CRC (Colorectal Cancer)

## Interventions

- **DRUG:** KQB365
- **DRUG:** Cetuximab
- **DRUG:** KQB198

## Key facts

- **NCT ID:** NCT06720987
- **Lead sponsor:** Kumquat Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-04
- **Primary completion:** 2029-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06720987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06720987, "A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06720987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*